Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

OTEZLA Film-coated tablets (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Otezla 10 mg film-coated tablets. Otezla 20 mg film-coated tablets. Otezla 30 mg film-coated tablets.

Qualitative and quantitative composition

Each film-coated tablet contains 10 mg of apremilast. Each film-coated tablet contains 20 mg of apremilast. Each film-coated tablet contains 30 mg of apremilast. Excipient(s) with known effect: Each film-coated ...

Pharmaceutical form

Film-coated tablet (tablet). Pink, diamond shaped 10 mg film-coated tablet of 8 mm length with APR engraved on one side and 10 on the opposite side. Brown, diamond shaped 20 mg film-coated tablet of 10 ...

Therapeutic indications

Psoriatic arthritis Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had ...

Posology and method of administration

Treatment with Otezla should be initiated by specialists experienced in the diagnosis and treatment of psoriasis or psoriatic arthritis. Posology The recommended dose of apremilast is 30 mg twice daily ...

Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Pregnancy (see section 4.6).

Special warnings and precautions for use

Patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. Diarrhoea, Nausea, and Vomiting There ...

Interaction with other medicinal products and other forms of interaction

Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast. Therefore, ...

Fertility, pregnancy and lactation

Women of childbearing potential Pregnancy should be excluded before treatment can be initiated. Women of childbearing potential should use an effective method of contraception to prevent pregnancy during ...

Effects on ability to drive and use machines

Apremilast has no or negligible influence on the ability to drive and use machines.

Undesirable effects

Summary of the safety profile The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%). These ...

Overdose

Apremilast was studied in healthy subjects at a maximum total daily dose of 100 mg (given as 50 mg BID) for 4.5 days without evidence of dose limiting toxicities. In case of an overdose, it is recommended ...

Pharmacodynamic properties

Pharmacotherapeutic group: Immunosupressants, selective immunosuppressants ATC code: L04AA32 Mechanism of action Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly ...

Pharmacokinetic properties

Absorption Apremilast is well absorbed with an absolute oral bioavailability of approximately 73%, with peak plasma concentrations (C<sub>max</sub>) occurring at a median time (t<sub>max</sub>) of approximately ...

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity. There is no evidencefor immunotoxic, dermal irritation, or phototoxic ...

List of excipients

Tablet core: Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Magnesium stearate Film-coating: Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3350 Talc Iron oxide red (E172) The ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 24 months.

Special precautions for storage

Do not store above 30°C.

Nature and contents of container

The treatment initiation pack contains 27 film-coated tablets (4 x10 mg, 4x 20 mg, 19 30 mg). Not all pack sizes may be marketed

Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Marketing authorization number(s)

EU/1/14/981/001

Date of first authorization / renewal of the authorization

Date of first authorisation: 15 January 2015

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: